Onderneming SELLAS Life Sciences Group, Inc.
Aandelen
SLS
US81642T2096
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,215 USD | +0,41% | -25,56% | +14,46% |
Vakgebied
Aantal werknemers: 16
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 03-04-06 |
John Burns
DFI | Director of Finance/CFO | 39 | 01-05-13 |
Andrew Elnatan
LAW | General Counsel | - | 05-01-23 |
Dragan Cicic
PRN | Corporate Officer/Principal | 60 | 10-02-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 29-12-17 | |
David Scheinberg
BRD | Director/Board Member | 68 | 01-12-17 |
John Varian
BRD | Director/Board Member | 64 | 29-12-17 |
Jane Wasman
CHM | Chairman | 67 | 29-12-17 |
Angelos Stergiou
FOU | Founder | 48 | 03-04-06 |
Katherine Kalin
BRD | Director/Board Member | 61 | 13-08-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 56 267 670 | 55 984 386 ( 99,50 %) | 0 | 99,50 % |
Bedrijfsgegevens
SELLAS Life Sciences Group, Inc.
Times Square Tower 7 Times Square
10026, New York
+
http://www.sellaslifesciences.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+14,46% | 68,08 mln. | |
-3,18% | 102 mld. | |
+1,28% | 96,29 mld. | |
+2,13% | 22,18 mld. | |
-15,73% | 21,2 mld. | |
-9,21% | 18,31 mld. | |
-39,98% | 17,38 mld. | |
-14,53% | 16,36 mld. | |
+4,64% | 13,97 mld. | |
+32,33% | 12,17 mld. |